Skip to main content

Advertisement

SpringerLink
Log in

Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage

  • ORIGINAL ARTICLE
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

In 12 of 93 hypercalcemic patients with metastatic advanced breast cancer treated with tamoxifen the most common life-threatening metabolic complication of flare hypercalcemia developed. All the hypercalcemic patients had osteolytic or mixed lytic and blastic bone metastases. In patients with advanced breast cancer, hypercalcemia develops within the first few weeks of initiation of tamoxifen therapy. In our study group, calcium levels were measured frequently in both serum and urine samples by a semi-autoanalyzer and an autoanalyzer, using standard methods. Elevation of calcium levels was noticed in the tamoxifen-receiving hypercalcemic breast cancer patients, and levels returned to normal when tamoxifen was withdrawn. The median duration of flare hypercalcemia was 9 days (range, 4–16 days). The median calcium value was 13.6 mg/dl (range, 11.7–15.8). The diagnosis of tamoxifen flare hypercalcemia was based on the normal pretreatment serum or urine calcium values and the occurrence of hypercalcemia within the first few weeks of tamoxifen initiation. There are no specific treatment recommendations for hormone flare hypercalcemia, except for tamoxifen withdrawal, which is usually temporary, and the introduction of a low dose of an antihypercalcemic drug. We evaluated the effect of such a drug, gallium nitrate, on flare hypercalcemia. All the patients were treated with hydration, and 6 patients, whose calcium level was above 13.6 mg/dl, were treated with a moderate dose of gallium nitrate (200 mg/m2 per kg) for 5 consecutive days, they achieved normocalcemia and continued with tamoxifen. The median time from hormonal drug initiation to flare hypercalcemia was 17.5 days, and median duration was 9 days. The above result indicates that the serious metabolic complication of hypercalcemia develops due to the iatrogenic effect of tamoxifen, but it can be controlled with an antihypercalcemic drug, gallium nitrate, while continuing tamoxifen therapy. It seems that the use of gallium nitrate in the treatment of flare hypercalcemia could allow safe readministration of tamoxifen and prevent premature tamoxifen discontinuance or withdrawal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. SS Legha HL Davis FM Muggia (1978) ArticleTitleHormonal therapy of breast cancer: new approaches and concepts Ann Intern Med 88 69–77 Occurrence Handle1:STN:280:CSeD2sfpvFw%3D Occurrence Handle339802

    CAS  PubMed  Google Scholar 

  2. J Jolivet S Legault-Poisson P Band (1978) ArticleTitleHormone therapy of breast cancer: tamoxifen Union Med Can 107 964–965 Occurrence Handle1:STN:280:CSaD3snls1M%3D Occurrence Handle705958

    CAS  PubMed  Google Scholar 

  3. D Plotkin JJ Lechner WE Jung PJ Rosen (1978) ArticleTitleTamoxifen flare in advanced breast cancer JAMA 8 IssueID240 2644–2646

    Google Scholar 

  4. M Sztern A Barkan E Rakowsky R Shainkin-Kestenbaum R Marilus I Blum (1981) ArticleTitleHypercalcemia in carcinoma of the breast without evidence of bone destruction: beneficial effect of hormonal therapy Cancer 1 2383–2385

    Google Scholar 

  5. RE Coleman RD Rubens (1987) ArticleTitleThe clinical course of bone metastases from breast cancer Br J Cancer 55 61–66 Occurrence Handle1:STN:280:BiiC38fnsFw%3D Occurrence Handle3814476

    CAS  PubMed  Google Scholar 

  6. G Kimmick HB Muss (1995) ArticleTitleCurrent status of endocrine therapy for metastatic breast cancer Oncology (Huntingt) 9 877–886 Occurrence Handle1:STN:280:BymD1Mfms10%3D

    CAS  Google Scholar 

  7. JL Bernheim W Callewaerts R Paridaens C Roobol (1983) ArticleTitleHuman mammary tumor growth promotion by medroxyprogesterone acetate in the tumor stem cell clonogenic assay Cancer Treat Rep 67 101–102 Occurrence Handle1:STN:280:BiuD3c3gtVY%3D Occurrence Handle6616491

    CAS  PubMed  Google Scholar 

  8. KI Pritchard RM Clark S Fine JW Meakin DJ Perrault DJ Sutherland (1978) ArticleTitleTamoxifen and hypercalcemia Ann Intern Med 89 423–424 Occurrence Handle1:STN:280:CSeB2Mrht10%3D Occurrence Handle686559

    CAS  PubMed  Google Scholar 

  9. HL Davis SuffixJr AN Wiseley G Ramirez FJ Ansfield (1973) ArticleTitleHypercalcemia complicating breast cancer. Clinical features and management Oncology 28 126–137 Occurrence Handle4270379

    PubMed  Google Scholar 

  10. S Legault-Poisson J Jolivet R Poisson M Beretta-Piccoli PR Band (1979) ArticleTitleTamoxifen-induced tumor stimulation and withdrawal response Cancer Treat Rep 63 1839–1841 Occurrence Handle1:STN:280:Bi%2BC3M%2Fps1A%3D Occurrence Handle230894

    CAS  PubMed  Google Scholar 

  11. JD Veldhuis RJ Santen (1979) ArticleTitleTamoxifen flare JAMA 8 IssueID241 2506–2507

    Google Scholar 

  12. HJ Lerner PR Band L Israel BS Leung (1976) ArticleTitlePhase II study of tamoxifen: report of 74 patients with stage IV breast cancer Cancer Treat Rep 60 1431–1435 Occurrence Handle1:STN:280:CSiC3snis1Q%3D Occurrence Handle798626

    CAS  PubMed  Google Scholar 

  13. SH Ralston SJ Gallacher U Patel J Campbell IT Boyle (1990) ArticleTitleCancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients Ann Intern Med 1 IssueID112 499–504

    Google Scholar 

  14. RE Coleman (1997) ArticleTitleSkeletal complications of malignancy Cancer 15 IssueID80 1588–1594

    Google Scholar 

  15. FM Muggia (1990) ArticleTitleOverview of cancer-related hypercalcemia: epidemiology and etiology Semin Oncol 17 3–9 Occurrence Handle1:STN:280:By%2BB3sblvFU%3D Occurrence Handle2185551

    CAS  PubMed  Google Scholar 

  16. KB Horwitz Y Koseki WL McGuire (1978) ArticleTitleEstrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen Endocrinology 103 1742–1751 Occurrence Handle1:STN:280:CSaC2cfit1c%3D Occurrence Handle748014

    CAS  PubMed  Google Scholar 

  17. DC Tormey RM Simon ME Lippman JM Bull CE Myers (1976) ArticleTitleEvaluation of tamoxifen dose in advanced breast cancer: a progress report Cancer Treat Rep Oct 60 1451–1459 Occurrence Handle1:STN:280:CSiC3snis1c%3D

    CAS  Google Scholar 

  18. Z Nikolic-Temasevic S Jelic I Popov D Radosavljevic L Mitrovic (2001) ArticleTitleTumor “flare” hypercalcemia – an additional indication for bisphosphonates? Oncology 60 123–126

    Google Scholar 

  19. Legha SS, Powell K, Buzdar AU, Blumenschein GR (1981) Tamoxifen-induced hypercalcemia in breast cancer. 47:2803–2806

  20. WJ Burtis TG Brady JJ Orloff JB Ersbak RP Warrell SuffixJr BR Olson TL Wu ME Mitnick AE Broadus AF Stewart (1990) ArticleTitleImmunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer N Engl J Med 19 1106–1112

    Google Scholar 

  21. NA Athanasou CA Wells J Quinn DP Ferguson A Heryet JO McGee (1989) ArticleTitleThe origin and nature of stromal osteoclast-like multinucleated giant cells in breast carcinoma: implications for tumour osteolysis and macrophage biology Br J Cancer 59 491–498 Occurrence Handle1:STN:280:BiaB38foslU%3D Occurrence Handle2713238

    CAS  PubMed  Google Scholar 

  22. JS Patterson BJ Furr LA Battersby (1978) ArticleTitleTamoxifen and hypercalcemia Ann Intern Med 89 1013 Occurrence Handle1:STN:280:CSaD28%2FlslI%3D Occurrence Handle717984

    CAS  PubMed  Google Scholar 

  23. LR Bernstein (1998) ArticleTitleRelated articles, links mechanisms of therapeutic activity for gallium Pharmacol Rev 50 665–682 Occurrence Handle1:CAS:528:DyaK1MXltFyhtg%3D%3D Occurrence Handle9860806

    CAS  PubMed  Google Scholar 

  24. P Collery B Keppler C Madoulet B Desoize (2002) ArticleTitleGallium in cancer treatment Crit Rev Oncol Hematol 42 283–296 Occurrence Handle12050020

    PubMed  Google Scholar 

  25. RP Warrell SuffixJr B Bosco S Weinerman B Levine J Lane RS Bockman (1990) ArticleTitleGallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis Ann Intern Med 113 847–851 Occurrence Handle2240900

    PubMed  Google Scholar 

  26. R Niesvizky CG Choy D Siegel (2002) ArticleTitleExtended survival in advanced-stage multiple myeloma patients treated with gallium nitrate Leuk Lymphoma 43 603–605 Occurrence Handle1:CAS:528:DC%2BD38XntVartL8%3D

    CAS  Google Scholar 

  27. Berheault-Cvitkovic F, Armand J-P, Tubuana-Hulin M (1996) Randomized, double blind comparison of pamidronate vs gallium nitrate for acute control of cancer-related hypercalcemia. Presented at the 9 EORTC/NC1 symposium, Amsterdam, March 1996

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biochemistry, Dr.A.L.M. Post-Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, 600 113, India

    Govinda Pillai Arumugam, Sengoden Sundravel & Panchanadham Sachdanandam

  2. Department of Pathology, A.L.M. Post – Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, India

    Palanivel Shanthi

Authors
  1. Govinda Pillai Arumugam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sengoden Sundravel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Palanivel Shanthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Panchanadham Sachdanandam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Panchanadham Sachdanandam.

About this article

Cite this article

Arumugam, G., Sundravel, S., Shanthi, P. et al. Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab 24, 243–247 (2006). https://doi.org/10.1007/s00774-005-0678-4

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-005-0678-4

Key words

Search

Navigation